

Pareto Securities AS initiates equity research coverage of ExpreS²ion with a Buy rating and target price of 60 SEK per share

Hørsholm, Denmark, June 24, 2021 – ExpreS²ion Biotech Holding AB (“ExpreS²ion”) hereby announces that Pareto Securities AS has published an equity research initiation report on ExpreS²ion. They initiate coverage with a Buy rating and a target price of 60 SEK per share.

The major contributors of value in the sum-of-the-parts valuation are ExpreS²ion’s 34% stake in its joint venture with NextGen Vaccines, AdaptVac, ExpreS²ion’s breast cancer vaccine candidate, ES2B-C001 HER2-cVLP, the company’s Influenza program as part of the INDIGO consortium, and royalties from the PREVENT-nCoV COVID-19 vaccine program.

The full English version of the company-sponsored equity research report is attached to this press release.

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se

For further information about ExpreS²ion, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS²ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.